Abstract 1367
Background
Primary bone cancers and bone metastases derived from advanced cancers have low survival rates. To answer medical need to treat tumors localized in bone environment, we have developed bone-targeted drugs through covalent binding to hydroxybisphosphonates known for their high affinity to bone. Objectives were improvement of efficacy and reduction of systemic toxicity.
Methods
Preclinical proof of concept of lead compound 12b80, an HBP-bound doxorubicin, was carried out on rodents and dogs. 12b80 was administered by IV injection every 3 weeks. Antitumor effects were investigated on various rodent models of bone cancer (orthotopic xenograft models of osteosarcoma or Ewing’s sarcoma, models of osteosarcoma-derived lung metastases and models of bone invasion by prostate or mammary adenocarcinoma) and on spontaneous osteosarcoma bearing dogs. Biodistribution was examined by radiolabeling and fluorescence analyses. Toxicity was evaluated by biological and clinical monitoring and histopathological analysis of organs.
Results
12b80 displayed rapid and sustained targeting of bone tissue and tumor-associated heterotopic bone, and permitted a higher doxorubicin payload in tumor bone environment. Doxorubicin release from 12b80 was dependent on acidic pH associated with active bone tumor environment. 12b80 showed a much lower and reversible toxicity compared with doxorubicin: mild medullar toxicity was recovered within two weeks and no sign of cardiotoxicity or osteonecrosis were observed in rodents and dogs. 12b80 promoted strong antitumor effects on rodent primary bone sarcoma (orthotopic osteosarcoma and Ewing sarcoma), osteosarcoma-derived lung metastasis and on prostate or breast adenocarcinoma bone invasion. 12b80 displayed a dose-response therapeutic effect and was more potent than combination of doxorubicin and zoledronate. First cases of tumor response were also reported in dogs currently under veterinary trial.
Conclusions
HBP-bound doxorubicin 12b80 demonstrated a proof of concept of preclinical bone-targeted doxorubicin delivery. The next step is to complete regulatory phase before starting 12b80 clinical trial (phase I/IIa) as an orphan drug in osteosarcoma salvage therapy.
Clinical trial identification
Legal entity responsible for the study
Atlanthera.
Funding
Atlanthera.
Editorial Acknowledgement
Disclosure
E. David, S. Cagnol, J-Y. Goujon, M. Egorov, R. Le Bot: Employment: Atlanthera.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract